EARNINGS: hVIVO CFO to retire; Personal Group sales and profit climb
15th Sep 2026 15:54
(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
| Price | 5.85p on 07-10-2026 at 08:18:35 |
|---|---|
| Change | 0.10p 1.74% |
| Buy | 6.00p |
| Sell | 5.70p |
| Last Trade: | Buy 6,837.00 at 5.85p |
| Day's Volume: | 518,111 |
| Last Close: | 5.75p |
| Open: | 5.75p |
| ISIN: | GB00B9275X97 |
| Day's Range | 5.75p - 5.85p |
| 52wk Range: | 4.35p - 10.00p |
| Market Capitalisation: | £40.27m |
| VWAP: | 5.905294p |
| Shares in Issue: | 688.40m |
Sector: Health Care and Related Services
Listed In: FTSE AIM 100, FTSE AIM All-Share,
hVIVO (HVO) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 6,837 | 5.85p | Ordinary |
09:18:34 - 07-Oct-26 |
| Buy* | 150,000 | 5.98p | Ordinary |
09:10:52 - 07-Oct-26 |
| Buy* | 2,282 | 5.90p | SI Trade |
09:07:34 - 07-Oct-26 |
| Buy* | 338 | 5.90p | SI Trade |
09:07:34 - 07-Oct-26 |
| Buy* | 4,237 | 5.90p | SI Trade |
09:07:34 - 07-Oct-26 |
| Buy* | 50,000 | 5.895p | Ordinary |
09:07:28 - 07-Oct-26 |
| Buy* | 200,000 | 5.89p | Ordinary |
09:06:23 - 07-Oct-26 |
| Sell* | 1,639 | 5.70p | Ordinary |
08:54:52 - 07-Oct-26 |
| Unknown* | 4,241 | 5.80p | Ordinary |
08:30:37 - 07-Oct-26 |
| Buy* | 12,076 | 5.90p | Ordinary |
08:23:51 - 07-Oct-26 |
hVIVO (HVO) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 22nd Sep 2026 7:00 am | RNS | Board Changes |
| 15th Sep 2026 7:01 am | RNS | Interim Results |
| 15th Sep 2026 7:00 am | RNS | Chief Financial Officer Succession |
| 8th Sep 2026 3:51 pm | RNS | Holding(s) in Company |
| 4th Sep 2026 7:00 am | RNS | Notice of Results |
| 27th Aug 2026 7:00 am | RNS | hVIVO acquires CRS Berlin |
| 23rd Jul 2026 7:00 am | RNS | H1 2026 Trading Update |
| 13th Jul 2026 7:00 am | RNS | Change of Auditor |
| 9th Jun 2026 7:00 am | RNS | Holding(s) in Company |
| 1st Jun 2026 12:00 pm | RNS-R | Consultancy contract with Decoy Therapeutics |